Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Zydus Lifesciences Limited Press Release Feb 20 2023

· Issued by Zydus Lifesciences Limited via NSE India

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release detailing two recent approvals from the USFDA for its pharmaceutical products. The first approval is for Gabapentin Tablets, which are indicated for managing Postherpetic Neuralgia, and will be manufactured at their facility in Moraiya.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases